CJC-1295 measurably increases growth hormone and IGF-1 levels in the small number of human studies that have tested it. In that narrow, pharmacological sense—doing what it was designed to do—it does work. Whether that hormonal effect translates to the broader outcomes people often associate with it, like muscle gain, fat loss, or anti-aging, is a separate question that current research simply doesn't answer. This distinction matters and informs each section below.
Does CJC-1295 really work?
Strictly assessed by its intended biological action—stimulating growth hormone release—CJC-1295 has direct human evidence confirming that it does indeed work. However, this relies on a small body of early-stage clinical research, rather than large-scale studies. The main human research involved two randomised, placebo-controlled, double-blind trials in healthy adults aged 21–61 years. Researchers tested single ascending doses and multiple dosing regimens over 28 and 49-day periods, and found that CJC-1295 induced dose-dependent increases in both growth hormone and IGF-1, with no serious adverse reactions reported [1]. A separate study added a significant detail: this hormone-boosting effect retained the body's natural pulsatile release pattern, rather than simply continuously flooding the system, while significantly raising the baseline level of growth hormone circulating between pulses [2].
Further supporting evidence comes from animal studies. In mice genetically engineered to lack GHRH – a model of growth hormone deficiency – daily injections of CJC-1295 normalised body weight and length compared to untreated animals, demonstrating that the compound has actual, measurable biological activity beyond the test tube [3].
Together, these discoveries support the assertion that CJC-1295 is pharmacologically active and indeed increases growth hormone and IGF-1. However, it is worth reiterating that „whether it works” in terms of visible physical results, treating diseases, or improving performance is a separate and far less studied question – one where the evidence is considerably more modest.
By how much does CJC-1295 increase HGH?
Human data show a clear, dose-dependent relationship between CJC-1295 and growth hormone secretion, although the exact magnitude is heavily dependent on dose and the method of measurement. In a primary human trial, a single injection induced mean plasma growth hormone elevations ranging from two- to tenfold above baseline, lasting for six days or longer, with the magnitude of the increase scaling upwards with higher doses [1]. IGF-1 — generally considered a more stable, long-term marker of growth hormone activity than growth hormone itself, as growth hormone is released in short pulses while IGF-1 rises gradually — increased from 1.5- to threefold and remained elevated for nine to eleven days following a single dose [1].
When CJC-1295 was administered repeatedly over several weeks, IGF-1 levels remained above baseline for up to 28 days. Researchers also noted evidence of a cumulative effect, meaning that repeated dosing built upon itself rather than simply repeating the same isolated spike each time [1].
A control study specifically analysing the pattern of hormone release added an interesting detail. Even during this sustained stimulation, growth hormone was still released in the body’s normal pulsatile bursts, rather than as a flat, continuous elevation. The frequency and amplitude of individual pulses remained roughly the same, but the „trough” level – the low point between pulses – rose dramatically, approximately 7.5-fold. This rise in the trough was identified as the major factor driving the overall increase in average growth hormone and the resulting rise in IGF-1 [2].
It is worth noting that the specific numbers above—the multiple increases and the days—come from one set of studies in one specific population of healthy adults, using specific dose levels, most significantly around 30–90 micrograms per kilogram. These numbers should not be assumed to generalize precisely to every dose, population, or administration schedule.
Benefits of CJC-1295 for women
There are no published human studies that have specifically analysed CJC-1295 in women or measured outcomes unique to female physiology. For this reason, it is not possible to make evidence-based statements about dosing, outcomes, or anti-ageing effects specifically for women. The main pharmacokinetic and hormonal studies on CJC-1295 recruited adult volunteers described generally as healthy, without reporting sex-specific analyses or separate sex-disaggregated outcome data [1], [2]. This gap is noteworthy, as growth hormone physiology can differ significantly between men and women.
For context, a separate study concerning another growth hormone stimulator, ipamorelin, specifically examined utilisation patterns by women based on data from online forums. It found that women using such compounds reported concerns regarding gender-specific effects on dosing and long-term consequences, with researchers calling for public health attention to this under-researched area [4]. This study, however, was a netnography—analysis of discussions in online forums—rather than a clinical or biological study, and it concerned a different peptide, not CJC-1295 directly.
Given the complete absence of dedicated clinical data regarding CJC-1295 in women, any claims of female-specific benefits, dosing protocols, or anti-ageing outcomes should be treated as unsupported by current evidence, rather than substantiated.
What happens when you stop taking CJC-1295?
No study identified in the peer-reviewed literature has directly measured what happens after people stop taking CJC-1295. Questions about „withdrawal effects” or the outcomes of cessation therefore cannot be answered with direct evidence at present. What can be reasonably inferred comes from the compound's known pharmacokinetics. As CJC-1295, in its long-acting, albumin-bound form, has an estimated half-life of approximately 5.8–8.1 days, its hormone-stimulating effects would be expected to gradually wane over one to several weeks after the last dose, rather than stop abruptly—since it takes time for the body to clear a compound with such a long half-life [1]. This is nevertheless a pharmacokinetic inference based on how the compound is cleared from the body, not a finding from a study that actually followed people after cessation. It should not be treated as confirmed.
Regarding the related question of using CJC-1295 „alone” versus in combination with a compound like ipamorelin, it's worth clarifying. The human studies that generated the main evidence for CJC-1295’s effects on growth hormone and IGF-1 tested it as a standalone compound, meaning that the hormonal data for standalone use described earlier in this article actually reflects CJC-1295 used by itself [1], [2]. Any additional effect that might come from combining it with another peptide has far more modest support, leaning primarily on animal data and mechanistic reasoning rather than direct comparative human studies.
Limitations of current evidence
The clearest and most convincing evidence for CJC-1295 pertains to its hormonal activity – that it does, in fact, increase growth hormone and IGF-1 in a dose-dependent, pulse-preserving manner in healthy adults.
Everything apart from this main finding is associated with considerably greater uncertainty. There are no dedicated studies in women. There is no controlled data on what happens after stopping the compound. And the evidence base in humans generally relies on a small number of early-stage studies rather than large, diverse, or long-term clinical trials. Readers should be cautious of sources that extrapolate well-supported hormonal findings to broader claims about sex-specific benefits or discontinuation effects, as these extrapolations are not yet supported by direct studies.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. CJC-1295 is a research compound and has not been approved by the FDA or the European Medicines Agency for any medical use. Human evidence is limited to a small number of early-stage studies measuring hormone levels in healthy adults, and no dedicated studies exist analysing its use in women, its effects upon discontinuation, or its long-term safety. Further research is required before definitive conclusions can be drawn.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogue. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[3] Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). *Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalises growth in the GHRH knockout mouse.*. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006
Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: Pulses and potions. Substance Use & Misuse, 51(1), 73–84. https://doi.org/10.3109/10826084.2015.1082595